Edgewise Therapeutics
EWTX
199 hedge funds and large institutions have $3.02B invested in Edgewise Therapeutics in 2025 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 69 increasing their positions, 54 reducing their positions, and 20 closing their positions.
140% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 20
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
66% more capital invested
Capital invested by funds: $1.82B → $3.02B (+$1.21B)
28% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 54
15% more funds holding
Funds holding: 173 → 199 (+26)
11% more call options, than puts
Call options by funds: $12.9M | Put options by funds: $11.6M
8.79% more ownership
Funds ownership: 106.28% → 115.07% (+8.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$41M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$40.2M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$39.4M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$23.2M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$19.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$25M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$14.7M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$14.6M |
| 4 |
Millennium Management
New York
|
-$12M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$8.28M |
EWTX Hedge Fund Activity: Q4 2025 in Review
199 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q4 2025, worth a combined $3.02B — up 66% from $1.82B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new EWTX positions and 20 closed out — a net gain of 28 holders — while 69 added to existing stakes and 54 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $41M. The largest seller was Bellevue Group, cutting an estimated $25M.
- 199 institutional investors held Edgewise Therapeutics (EWTX) as of Q4 2025, up from 173 in Q3 2025.
- Funds reported $3.02B of Edgewise Therapeutics stock for Q4 2025, up 66% quarter-over-quarter.
- 48 funds opened new Edgewise Therapeutics positions in Q4 2025 and 20 closed out, a net change of +28 holders.
- The largest Edgewise Therapeutics buyer in Q4 2025 was Morgan Stanley, an estimated $41M added.
- The largest Edgewise Therapeutics seller in Q4 2025 was Bellevue Group, an estimated $25M sold.
Based on aggregated 13F filings for Q4 2025.